- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about LLY
Recent news which mentions LLY
Could Elon Musk Become The World's First Trillionaire? Tesla's Success Could Make It Happen As Early As...
September 11, 2024
From Benzinga
Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy
September 11, 2024
From Benzinga
Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound)
September 11, 2024
Tickers
LLY
From Motley Fool
Is Hims & Hers Health the Next Teladoc?
September 11, 2024
From Motley Fool
Prediction: These 2 Companies Will Split Their Stocks by 2027
September 11, 2024
From Motley Fool
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
September 11, 2024
From Benzinga
From Benzinga
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
September 09, 2024
From Benzinga
A Glimpse Into The Expert Outlook On Eli Lilly Through 28 Analysts
September 09, 2024
Tickers
LLY
From Benzinga
Tickers
LLY
From Motley Fool
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
September 08, 2024
Tickers
LLY
From Motley Fool
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
September 07, 2024
From Motley Fool
Innovent Bio hopes for plus-sized profits from obesity drug
September 06, 2024
From Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
From Benzinga
Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed
September 06, 2024
Tickers
LLY
From Benzinga
Comparative Study: Eli Lilly And Industry Competitors In Pharmaceuticals Industry
September 06, 2024
From Benzinga
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem
September 06, 2024
Tickers
LLY
From Motley Fool
From Benzinga
From Benzinga
Eli Lilly's Once-Weekly Insulin Shows Non-Inferior Blood Sugar Reduction Vs Frequently Used Daily Insulins In Long Term Trials
September 05, 2024
From Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
September 05, 2024
From Motley Fool
Why Walgreens Boots Alliance Fell Another 22% in August
September 05, 2024
From Motley Fool
From Benzinga
Trade Pulse Power Inflow Alert: Eli Lilly Stock Rises Over 7 Points
September 04, 2024
Tickers
LLY
From Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 03, 2024
From Benzinga
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
September 02, 2024
From Benzinga
2 No-Brainer Growth Stocks to Buy With $1,000 Right Now
September 01, 2024
From Motley Fool
3 No-Brainer Stocks to Buy in September
August 31, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.